secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2026-08-04T11:02:52+00:00
Accession:  0001193125-26-331516
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar Q2 net loss $32.8M; nomlabofusp BLA rolling submission underway
-----------------------------------------------------------------------

- Net loss $32.8M ($0.30/sh) vs $26.2M ($0.41/sh) in Q2 2025; cash $156.3M, runway into Q3 2027.
- Open-label study: 43 participants dosed; 82% achieved skin FXN above asymptomatic carriers at 6 months, 100% at 1 year.
- mFARS benefit of 2.6 points at 1 year vs natural history; no withdrawals from injection site reactions.
- Rolling BLA for accelerated approval started; completion expected 2H 2026; confirmatory Phase 3 first patient dosing expected Q3 2026.
- Targeting mid-2027 launch if approved; FDA agreed FXN as surrogate endpoint.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000119312526331516/0001193125-26-331516-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000119312526331516/lrmr-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-331516

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer